Direct-to-consumer health-care startup Ro on Wednesday said its platform will now offer more affordable single-dose vials of the weight loss drug Zepbound through a new partnership with Eli Lilly, which aims to streamline access to the popular treatment. Ro said it will offer a "complete end-to-end" experience on a single platform and app, allowing eligible patients to receive a diagnosis and a prescription for Zepbound and have vials of the drug delivered to their homes. That is made possible through a fir ...

礼来（LLY） 首发报告 替尔泊肽将继续拉动公司收入快速增长 24 年 Q3 收入+20%至 114.4 亿美元：24 年 Q1 收入同比+20%至 114.4 亿美元，2023 年 Q3 出售奥氮平产品组合 (Zyprexa) 权利带 来的 14.2 亿美元收入，如果不包括奥氮平收入，则 Q3 总收入增长 42% ， 全 球 销 量增长 36%, 销 量 增 长 主 要 得 益 于 Mounjaro 和 Zepbound 的增长,但是非 GLP-1 产品的收入也增长了 17%（包括肿 瘤学、免疫学和神经科学产品组合）。有利的产品组合和价格致使 毛利率同比+0.6 个百分点至 81.0%，研发费用同比+14%至 27.3 亿美 元，研发费率同比-1.5 个百分点至 23.9%，因收购 Morphic 公司 （α4β7 整合素小分子）导致收购在研项目研发费用达 28.3 亿美 元。销售管理费用同比增长 16.4%至 21.0 亿美元，S&GA 费率同比下 降 0.6 个百分点至 18.4 %。综上所述，公司 GAAP 净利润同为 9.7 亿 美元，EPS 为 1.07 美元，24 年 1 季度公司分红 10 亿 ...

Eli Lilly and Company (LLY) announced that its popular obesity drug, Zepbound (tirzepatide) demonstrated more weight loss than rival Novo Nordisk’s (NVO) Wegovy in a first-ever head-to-head obesity study, SURMOUNT-5. Zepbound is a dual GIP and GLP-1 receptor agonist, while Wegovy is a mono GLP-1 receptor agonist.In the phase IIIb 72-week study, Zepbound led to an average weight loss of 20.2% of body weight in adults with obesity or overweight, compared to 13.7% for Wegovy, which represents a 47% greater rel ...

Unsurprisingly, these stock pickers are capitalizing on an opportunity that's only recently become addressable.Just because a bunch of billionaires all own the same stock doesn't necessarily mean it's a great pick for you. On the other hand, most billionaires have become and remained billionaires for a reason. It wouldn't be wrong to at least explore one of only a handful of names this ultrarich crowd can agree is worth owning.To this end, drugmaker Eli Lilly (LLY 2.03%) is currently one of several billiona ...

If you like what you have just read and want to receive at least 4 exclusive stock tips every week focused on Pharma, Biotech and Healthcare, then join me at my marketplace channel, Haggerston BioHealth . Invest alongside the model portfolio or simply access the investment bank-grade financial models and research. I hope to see you there.The group is for both novice and experienced biotech investors. It provides catalysts to look out for and buy and sell ratings. It also provides product sales and forecasts ...

Key TakeawaysPatients taking Eli Lilly's Zepbound lost more weight on average than those on Novo Nordisk's Wegovy in a new clinical study.Zepbound patients lost an average 20% of their body weight compared with roughly 14% for those on Wegovy.Both weight-loss drug makers' stocks have slipped in recent months, but they remain in positive territory for the year. Eli Lilly's (LLY) popular weight-loss drug Zepbound outperformed Wegovy, a competitor drug from Danish drugmaker Novo Nordisk (NVO), according to the ...

The weight-loss drug market is about to get even more crowded. Eli Lilly & Co (NYSE:LLY) stock is up 2.2% at $830.80, after a news release reported the company's weight-loss drug Zepbound rivaled Novo Nordisk's (NVO) Wegovy in a head-to-head trial. The treatment achieved an average weight loss of 20.2% at 72 weeks in adults with obesity without diabetes, while its rival managed 13.7%. Eli Lilly stock has been rebounding since its early-November nine-month lows, now headed for its sixth win in the last seven ...

The magic isn't over for Eli Lilly (LLY 1.69%). Though the pharmaceutical giant isn't performing as well in the second half of the year as it did in the first, it still has plenty of fuel for growth. In fact, the drugmaker recently received some welcome news that jolted its stock price.The bears might point out that Eli Lilly's shares still look too expensive: The company's trailing price-to-earnings (P/E) ratio tops 86 -- the average for the healthcare industry is less than a quarter of that at 18.Do recen ...

Eli Lilly on Wednesday said its obesity drug Zepbound led to more weight loss than its main rival, Novo Nordisk's Wegovy, in the first head-to-head clinical trial on the weekly injections. The findings suggest Zepbound may be a superior treatment for weight loss, helping obese or overweight patients lose 20.2% of their body weight, or roughly 50 pounds, on average after 72 weeks in the phase three trial. Meanwhile, Wegovy helped people lose 13.7% of their weight, or about 33 pounds, on average after the sam ...

JR Research is an opportunistic investor. He was recognized by TipRanks as a Top Analyst. He was also recognized by Seeking Alpha as a "Top Analyst To Follow" for Technology, Software, and Internet, as well as for Growth and GARP. He identifies attractive risk/reward opportunities supported by robust price action to potentially generate alpha well above the S&P 500. He has also demonstrated outperformance with his picks. He focuses on identifying growth investing opportunities that present the most attracti ...